The Future of Vision Therapy Care - Eyecarrot
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
The Future of Vision Therapy Care
Safe Harbour
This confidential business presentation (the “Presentation”) has been prepared by Eyecarrot Innovations Corp. (“Eyecarrot”). others: uncertainties and assumptions in our revenue forecasts; defects or disruptions in our proposed products and services;
The Presentation is being provided by Eyecarrot for general background informational purposes only and for use by a limited risks that we may be unable to raise additional financing should our expected revenues not materialize; risks related to loss or
number of parties that may be interested in the business of Eyecarrot. The information set forth is considered confidential and infringement of our intellectual property or Eyecarrot’s infringement of intellectual property belonging to third parties; our
is not intended for distribution. This Presentation and the information contained herein shall not be copied, reproduced in any dependence on key personnel and the risk of conflicts of interest; competition in our industry; market price volatility of the
way or distributed, directly or indirectly, to others at any time. Upon request the recipient will promptly return to Eyecarrot all common shares; global economic and financial market conditions; failure to manage our growth successfully; Eyecarrot’s
material received from Eyecarrot (including this Presentation) without retaining any copies thereof. ability to pay dividends; and currency exchange rate fluctuations.
Statements involving forward-looking information are based on current expectations and entail various risks and uncertainties.
All references to currency in this document are to Canadian dollars unless otherwise indicated. Actual results may vary from the forward –looking information and materially differ from expectations, if known and unknown
risks or uncertainties affect our business, or if our estimates or assumptions prove inaccurate. Eyecarrot assumes no obligation
Statements in this Presentation are made as of the date hereof unless stated otherwise and the delivery of this Presentation to update or revise any forward-looking information, whether as a result of new information, future events or any other reason.
shall not under any circumstances create an implication that the information contained herein is correct as of any time
subsequent to its date. In furnishing this Presentation, Eyecarrot does not undertake or agree to any obligation to provide the The Presentation has not been independently verified and the information contained within is subject to updating, completion,
attendee with access to any additional information or to update this Presentation or to correct any inaccuracies in, or revision, verification and further amendment. Neither Eyecarrot, nor its shareholders, directors, officers, agents, employees, or
omissions from, this Presentation that may become apparent either during, or at any time after this Presentation. advisors give, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to,
the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or
Certain statements contained in this Presentation may constitute forward-looking statements or forward-oriented financial oral information made or to be made available to any interested party or its advisers (all such information being referred to as
information. These statements relate to future events or Eyecarrot’s future performance. All statements, other than statements (“Information”) and liability therefore is expressly disclaimed.
of historical fact, may be forward-looking statements. Forward-looking statements are often, but not always, identified by the
use of words such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “propose”, Certain information contained in this Presentation with respect to other companies and their business and operation has been
“potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe” and similar expressions. Forward-looking statements obtained or quoted from publicly available sources, such as continuous disclosure documents, independent publications,
should not be unduly relied upon as actual results may vary significantly. Forward-looking statements in this Presentation and media articles, third party websites (collectively, the “Publications”). In certain cases, these sources make no representations as
the documents incorporated by reference herein include but are not limited to statements relating to: Eyecarrot’s expectations to the reliability of the information they publish. Further, the analyses and opinions reflected in these Publications are subject to
with respect to the performance of its cameras; expectations regarding its revenue, expenses and operations; anticipated cash a series of assumptions about future events. There are a number of factors that can cause the results to differ materially from
needs and its needs for additional financing; its ability to protect, maintain and enforce its intellectual property rights; those described in these publications. None of Eyecarrot or its representatives independently verified the accuracy or
Eyecarrot’s ability to defend itself against third-party claims of infringement or violation of, or other conflicts with, intellectual completeness of the information contained in the Publications or assume any responsibility for the completeness or accuracy
property rights by Eyecarrot; its plans for and timing of expansion of its product offering and value-added services; its future of the information derived from these Publications.
growth plans; the acceptance by its customers and the marketplace of new satellite imaging content, technologies and
solutions; its ability to attract new customers; its ability to attract and retain personnel; its competitive position and its Neither the communication of this Presentation nor any part of its contents is to be taken as any form of commitment on the
expectations regarding competition; regulatory developments and the regulatory environments in which Eyecarrot operates; part of Eyecarrot to proceed with any transaction. This Presentation does not constitute, or form part of, any offer or invitation
and anticipated trends and challenges in its business and the markets in which it operates. Such statements reflect our current to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company, nor shall it, or the
views with respect to future events, and in some cases information supplied by third parties, and are subject to risks and fact of its communication, form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any
uncertainties. Such statements are necessarily based upon a number of estimates and assumptions (including that information contract or commitment whatsoever with respect to such securities.
received from third parties and publicly available information is reliable) that, while considered reasonable by Eyecarrot, are
inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this Presentation.
Many factors could cause our actual results, performance or achievements to be materially different from any future results,
performance, or achievements that may be expressed or implied by such forward-looking statements, including, among
TSX.V : EYC | OTCQB: EYCCF 2
Did You Know?
Our Simple Vision Testing Data is changing the lives of millions
16 year old Hockey Player Loses 12 months of his Life
• 9 months of brain therapy did nothing
• 10 minute eye exam changed everything!
Misdiagnosed with ADHD and medicated for years,
Vision TherapyChanged his life
• #AtticusAct is now lobbying to save Maryland billions in healthcare costs
• 3-4 million kids on ADHD medication when treatment is available!!
On the Autistic Spectrum…but genius level performance
• Faster hands than a gold medal boxer?
• How did our technology change his life?
TSX.V: EYC | OTCQB: EYCCF 3
Did You Know?
Super professional athletes stand by our technology
One of the greatest NFL Wide Receivers trained on our
technology to fix his vision related learning disability!
• Super hand eye coordination was trained
• Now a major advocate for vision screening
Captain of the NJ Devils, did not make his comeback to NHL
until he completed intensive Vision Therapy
• Developed better vision skills than before at age 35!
• Signed the largest contract of his life and led team to Stanley Cup finals
MLB All Star Raul Ibanez leveraged our technology for
his best years in Baseball
• Elevated his game with new found vision skills
• Now a major advocate for vision skills training with Binovi
TSX.V: EYC | OTCQB: EYCCF 4
Facts
Addressing a problem that affects millions of people globally
Treatable Undiagnosed Binocular Vision Problems are prevalent in 1 in 4 people
SOURCE: College of Optometrists in Vision Development
5 of the 9 symptoms of ADHD are the same as treatable Binocular Vision Problems
SOURCE: American Optometric Association
Pharmaceutical industry expects to reap $9.4B by 2020 on ADHD drugs
SOURCE: CNBC
Why is this not picked up in routine Eye Exams?
TSX.V: EYC | OTCQB: EYCCF 5
What is Being Tested?
A standard eye exam tests for structure issues, and disease, not functional problems
VISUAL ACUITY TEST - This is the standard 20/20 letters on a wall test. How clearly you see at a fixed distance.
RETINOSCOPY - A retinoscopy allows the optometrist to approximate your optimal lens prescription.
REFRACTION TEST - A test to allow the prescription of lenses for nearsightedness, farsightedness, or astigmatism.
KERATOMETRY TEST - This test measures the shape and curve of the outside of the eye, known as the cornea and
allows for Optometrists to detect astigmatism.
INTRAOCULAR PRESSURE MEASUREMENT - An intraocular pressure test measures the force or pressure created by the fluid
in your eyes. An abnormal level of eye pressure can be a warning sign of glaucoma.
However, what if we are talking about ADHD? How does the patient see the world?
TSX.V: EYC | OTCQB: EYCCF 6
Functional Vision Problems
The structure of the eye can be perfect, but the function is the problem
Functional Vision Problems can be classified into 3 main groups
Oculomotor Dysfunctions - “Tracking and Eye Movements”
Accommodative Dysfunctions - “Focusing”
Binocular Vision Disorders - “Eye Coordination and Alignment”
TSX.V: EYC | OTCQB: EYCCF 7
Symptoms Resemble ADHD
Is this ADD/ADHD or is it a treatable vision issue?
TRY IT YOURSELF NOW
Imagine trying to read something like this:
TRYING TO READ WHEN YOU HAVE A
TRYING TO READ WHEN YOU HAVE A
TRACKING PROBLEM MAY CAUSE YOU
TRACKING PROBLEM MAY CAUSE YOU
TO RE-READ WORDS, LINES, AND See if you can make a 3rd
TO RE-READ WORDS, LINES, AND
REDUCES YOUR Finger appear in between
REDUCES YOUR
COMPREHENSION, CAUSING A CHILD TO Your 2 fingers
COMPREHENSION, CAUSING A CHILD TO
NOT WANT TO READ AND, EVENTUALLY,
NOT WANT TO READ AND, EVENTUALLY,
BEHAVIOUR PROBLEMS
BEHAVIOUR PROBLEMS
TSX.V: EYC | OTCQB: EYCCF 8
Visual Skills
EYE MOVEMENT CONTROL The ability to move both eyes together to point at an independent target or follow along a path, like a line of text
SIMULTANEOUS FOCUS (FAR) Forming a clear image of something in the distance
SUSTAINING FOCUS (FAR) Keeping a clear image of something in the distance
SIMULTANEOUS FOCUS (NEAR) Forming a clear image of something close to the eyes
SUSTAINING FOCUS (NEAR) Keeping a clear image of something close to the eyes
SIMULTANEOUS ALIGNMENT (FAR) Lining up both eyes at the same point in the distance The Main Skill Tested
During an Eye Exam
SUSTAINING ALIGNMENT (FAR) Holding both eyes lined up at the same point in the distance
SIMULTANEOUS ALIGNMENT (NEAR) Lining up both eyes at the same point up close
SUSTAINING ALIGNMENT (NEAR) Holding both eyes lined up at the same point up close
CENTRAL VISION (VISUAL ACUITY) Clarity in the visual image, “20/20” vision
PERIPHERAL VISION Being able to see to either side while he eyes are pointed forwards
DEPTH AWARENESS Depth perception, being able to tell that things are farther away or close up
COLOUR PERCEPTION Being able to tell different colours apart (for non colour-blind individuals)
GROSS VISUAL-MOTOR Moving through space without bumping into things using visual information
FINE VISUAL-MOTOR Writing, sewing, texting, or doing other small, close-up activities with accuracy
VISUAL PERCEPTION Being aware of the environment and what is going on in the visual field
VISUAL INTEGRATION Bringing together vision and other senses to accomplish tasks, like reading while walking a balance beam
TSX.V: EYC | OTCQB: EYCCF 9
The Solution: “The Binovi Platform”
Here’s how Binovi helps Optometrists, Therapists, and Patients
SCREENING + TESTING ASSESSMENT + TRAINING CARE + MAINTENANCE
IP Based Vision Performance Screening
Licensed Therapy Video Library Patient Care Platform via Binovi Coach
Digitized Testing Infrastructure
Vision Performance Hardware since 1974 Doctor-prescribed personalized home therapy plan
Globally Standardized Symptom Questionnaire
(new release 2018)
(Q4 2018)
10ADHD Protocol: Identify The Vision Deficiency
Binovi screening and testing makes it easy to identify the problem
BINOVI IN-APP TESTING INCORPORATES THE FOLLOWING:
• Dynamic Depth Perception Testing using 3D projection
• Vergence Facility, Visual Memory, Figure Ground Testing
• Mobile First Software leveraging iOS/Android
• Complete screening takes a total of 2-3 mins
SYMPTOM QUESTIONNAIRE
Binovi in-App Symptom Survey
• Deployable forms for patient symptom tracking
• Partnership with leading global organizations to leverage standardized
symptom questionnaires
• ADHD symptoms often resemble vision issues; the questionnaire
helps identify these symptoms
11ADHD Protocol: Assess & Train the Specific Skills
Binovi ODs train the skills with hardware and expert video instructions
BINOVI HARDWARE TRAINING
Binovi Touch Saccadic Fixator: standard since 1974!
• Hardware is wall mounted light board trainer
• Replicates what happens in a school environment and trains the
skills necessary to acquire information from the blackboard
• ADHD patients require accommodative skills; our hardware and
software trains these
• 2018 new release has a full spectrum of features including Training,
Assessing, Reporting and full Customization
BINOVI SOFTWARE TRAINING
Binovi Pro includes full spectrum of videos for skill development
• Binovi Pro hosts world class vision therapy library with content from
top educators
• Allow for OD to prescribe week by week home therapy instructions
• Features include secure video, messaging, compliance tracking,
progress evaluation
12ADHD Protocol: Trains the skills at home
Patient care and maintenance
PATIENT CENTRIC DESIGN
Binovi Coach - Patient Care Platform
• OD Prescribed Activities progress the patient through treatment plans
• Allows for complete customization controlled by the care team
• Offers a tiered training structure
• Daily time tracking, secure messaging, reminders
• Guardian Infrastructure is in place to enable collaborative care and
patient centric sharing
13Launching Binovi Academy
Expanding from 1 library to 5 advanced educational libraries which will expand our leadership team
Foundational Home Vision Therapy Library (>120 videos)
Dr. Robert Sanet (Now Complete and in the App store)
Dr. Len Press Academic Theory from his book “Applied
Concepts in Vision Therapy” for Therapist Training
Advanced Primitive Reflex Library (Occupational Therapy) - filmed and
released in early 2018
Advanced Sports Vision Training Library (ISVA*)
Functional Syntonic Optometry Library (Neuro-photonics)
14Business Model & Revenue Scenarios
SOFTWARE SUBSCRIPTION - $99/MONTH HARDWARE ONE-TIME
Binovi Coach: $100/patient/year Saccadic: $3,000 per device
100 @ 3 PATIENTS / MONTH = $478,800/YR $300 K
Number of Clinics
250 @ 3 PATIENTS / MONTH = $1.2 MM/YR $750 K
500 @ 3 PATIENTS / MONTH = $2.4 MM/YR $1.50 MM
1500 @ 3 PATIENTS / MONTH = $7.18 MM/YR $4.50 MM
15
1 Acquired Wayne Engineering, creator of Saccadic Fixator, and Industry Standard since 1974
* All figures are in USD Dollars 15Eyecarrot Team
Management Team and Board of Directors Special Advisors
Adam Cegielski, BSc Dr. Robert Sanet, O.D., F.C.O.V.D.
CEO & DIRECTOR SPECIAL ADVISOR - BEHAVIOURAL OPTOMETRY & VISION TRAINING
Sam Mithani, PhD Dr. Leonard Press, O.D., F.C.O.V.D.
CTO & DIRECTOR DIRECTOR OF GLOBAL EDUCATION
Dr. Selwyn Super, D.Optom., B.Ed., M.Ed., PhD Dr. Patrick Quaid, MCOptom, F.C.O.V.D., PhD
CHIEF SCIENTIFIC OFFICER SPECIAL ADVISOR - BINOCULAR VISION
Dr. John G. Flanagan, OD, PhD, DSc(hon), FCOptom, FAAO Bryce Salvador, Former Captain NHL New Jersey Devils
DIRECTOR SPORTS ADVISOR
David Schmidt, BSc Joe Lia, Producer of Survivor series
DIRECTOR VIDEO PRODUCTION
Sean Charland Todd Finch, Technology Leader
DIRECTOR STRATEGIC ADVISOR
TSX.V: EYC | OTCQB: EYCCF 16Capital Structure - Q2 2018
Share Price Share Structure
$0.70 1,500,000
Shares Outstanding 94,265,363
$0.60
1,200,000
$0.50
Warrants @ $0.20 (Exp Nov 2019) 16,135,000
900,000
$0.40
Warrants @ $0.30 (Exp Feb 2020) 2,711,667
$0.30
600,000
$0.20
Options @ $0.25 6,510,000
300,000
$0.10
Total Fully Diluted 114,785,298
$0.00
17Software Benefits
TSX.V: EYC | OTCQB: EYCCF 18Hardware Benefits
COMPLETE CONTROL LIVE DATA FEED
FULL CONNECTIVITY REPORTING
TSX.V: EYC | OTCQB: EYCCF 19© 2017 Eyecarrot Innovations Corp. February 2018
You can also read
